RESEARCH · NAD+ · KIDNEY AND ACUTE KIDNEY INJURY
NAD+ and the Kidney: De Novo Synthesis, QPRT, Urinary Quinolinate and Acute Kidney Injury Research
PurixLab’s NAD+ 500mg is a research vial of the coenzyme nicotinamide adenine dinucleotide. Our earlier articles cover NAD+ coenzyme biology, membrane transport, NR and NMN precursor trials and age-related decline in human tissue. This article looks at one organ where NAD+ research has moved from mouse genetics to urine metabolomics and small clinical studies: the kidney, and in particular acute kidney injury (AKI). These are findings from published research; the vial is supplied for laboratory research use only, and nothing here is treatment guidance or a claim about any PurixLab product.
Why the kidney?
Renal tubules spend a great deal of energy concentrating solutes against gradients, which may make the kidney especially vulnerable to ischaemia, and AKI affects 3% of all hospitalised patients [1]. In mice, the mitochondrial biogenesis regulator PGC1α turned out to be a determinant of recovery after renal ischaemia. Pgc1α knockout mice developed a local deficiency of nicotinamide (NAM), fat accumulation and failure to regain normal function, while tubular PGC1α transgenic mice had more local NAD and better function. PGC1α upregulated the enzymes that make NAD de novo from amino acids, and NAM given to the knockout mice improved local NAD levels and renal function [1].
The de novo pathway and its bottleneck, QPRT
Most textbook accounts treat NAD+ synthesis from tryptophan as a minor route in mammals, with recycling from NAM doing most of the work. The kidney work challenged that view. After murine AKI, renal NAD+ fell, quinolinate rose and the bottleneck enzyme quinolinate phosphoribosyltransferase (QPRT) declined; mice lacking one copy of the QPRT gene had higher quinolinate, lower NAD+ and greater AKI susceptibility [2]. A later study found QPRT expression fell in two unrelated AKI models, that conditional gain-of-function mice were protected, and that a PGC1α to HNF4α to QPRT axis controlled NAD+ levels and cellular ATP [3].
A second control point sits one step earlier. The enzyme ACMSD limits the flow of tryptophan metabolites into NAD+; genetic or pharmacological inhibition of ACMSD boosted de novo synthesis and sirtuin 1 activity in worms and mice. Because ACMSD expression is largely restricted to kidney and liver, the authors proposed these tissues as targets for injury protection [4].
Why does QPRT fall? One group provided evidence that the endoplasmic reticulum stress response may repress QPRT transcription, and persistent reduction of QPRT expression was associated with progression from AKI to chronic kidney disease (CKD) [5].
A urine marker: the quinolinate-to-tryptophan ratio
If QPRT activity falls, its substrate quinolinate should accumulate relative to tryptophan. An elevated urinary quinolinate/tryptophan ratio (uQ/T) predicted AKI and other adverse outcomes in critically ill patients [2]. The same signal has since been reported in several settings:
- Cardiac surgery and transplantation. A high uQ/T was an early marker of AKI after cardiac surgery and predicted progression to CKD in kidney transplant recipients [5].
- COVID-19. In a case-control study (14 cases and 14 controls in Boston, 8 cases and 10 controls in Birmingham), the median uQ/T was 1.34 in AKI cases versus 0.31 in controls (P = 0.0013) [6].
- Vascular surgery. In a small matched case-control study, postoperative uQ/T was higher in patients who developed AKI (p = 0.04), although preoperative values did not differ [7].
- Upstream metabolites. In 167 cardiac bypass patients, urinary tryptophan and kynurenine were lower in those who developed AKI, with an AUC of 0.82 and 0.75 for discriminating any-stage AKI [8].
These are associations in modest cohorts, measured by liquid chromatography-mass spectrometry, and none establishes that low renal NAD+ causes human AKI.
Precursor studies in animal models
Results from NAD+ precursor experiments in rodents are mixed:
- Kidneys of 20-month-old mice had lower SIRT1 and NAD+ than those of 3-month-old mice. NMN restored renal NAD+ and SIRT1 activity and protected both age groups from cisplatin-induced AKI, and SIRT1 deficiency blunted the protection [9].
- In rats with bilateral ischaemia-reperfusion, prophylactic nicotinamide riboside (NR) restored tissue NAD+ and increased autophagy, but did not reduce tubular damage or profibrotic gene expression at 24 hours or 14 days [10].
- In mice with ischaemic AKI, NAM had no effect on renal function, histology or injury markers and did not increase post-AKI kidney NAD+ [8]. An accompanying editorial noted that earlier positive reports had not measured kidney NAD+, filtration and histology together in wild-type mice [11].
NAD+ biology in the kidney is not limited to AKI. In diabetic mice, sirtuin 1 in proximal tubules fell before albuminuria appeared, and the authors traced a retrograde signal from tubules to glomeruli carried by NMN that influenced podocyte function [12].
Early human studies
- Oral NAM, phase 1. A placebo-controlled phase 1 study reported an increase in circulating NAD+ metabolites; NAM was well tolerated and associated with less AKI; as a phase 1 study it was not designed to establish efficacy [2].
- NR with pterostilbene. In 24 hospitalised patients with AKI, whole-blood NAD+ fell by 50% at 48 h with placebo, and across all active steps it rose by 37% (p = 0.002). Safety laboratory tests were unchanged and 3 of 20 active-treatment patients reported minor gastrointestinal effects. The study was not designed to test kidney outcomes [13].
- Niacinamide in COVID-19 AKI. In a nonrandomised, quasi-experimental study of 201 patients, death or kidney replacement therapy occurred in 38 of 90 niacinamide patients and 62 of 111 comparison patients (HR 0.64, 95% CI 0.40 to 1.00). The authors state that randomised studies are needed to establish causality [14].
- NR in CKD. In a crossover trial in 25 patients with an eGFR below 60, six weeks of NR did not change peak oxygen consumption or eGFR compared with placebo, although it altered NAD+-linked metabolites and lipid groups [15].
What remains open
- Whether uQ/T reflects renal QPRT activity specifically, or also systemic tryptophan metabolism and urine handling.
- Why NAM protected mice in some models but not in others, and whether kidney NAD+ actually rises in the injured tissue.
- Whether any precursor changes hard kidney outcomes; the human studies above are small, short or nonrandomised.
- How the de novo and salvage pathways divide the work in human tubules, and whether the ACMSD and QPRT control points behave as they do in mice.
Most of this work uses precursors such as NAM, NR or NMN rather than NAD+ itself, and none of it tested a research-grade NAD+ vial.
NAD+ 500mg at PurixLab
NAD+ 500mg: a labelled lyophilized research vial with 500mg per vial, C$109 per vial (CAD, before tax), supplied for laboratory research only. NAD+ is a coenzyme, not a peptide. Batch documentation is available on request. Product page: purixlab.com/product/nad-500mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Tran MT, Zsengeller ZK, Berg AH, et al. PGC1α drives NAD biosynthesis linking oxidative metabolism to renal protection. Nature. 2016;531(7595):528-32. PubMed 26982719 · PMC4909121 · doi:10.1038/nature17184
- Poyan Mehr A, Tran MT, Ralto KM, et al. De novo NAD+ biosynthetic impairment in acute kidney injury in humans. Nat Med. 2018;24(9):1351-1359. PubMed 30127395 · PMC6129212 · doi:10.1038/s41591-018-0138-z
- Clark AJ, Saade MC, Vemireddy V, et al. Hepatocyte nuclear factor 4α mediated quinolinate phosphoribosylltransferase (QPRT) expression in the kidney facilitates resilience against acute kidney injury. Kidney Int. 2023;104(6):1150-1163. PubMed 37783445 · PMC10843022 · doi:10.1016/j.kint.2023.09.013
- Katsyuba E, Mottis A, Zietak M, et al. De novo NAD+ synthesis enhances mitochondrial function and improves health. Nature. 2018;563(7731):354-359. PubMed 30356218 · PMC6448761 · doi:10.1038/s41586-018-0645-6
- Bignon Y, Rinaldi A, Nadour Z, et al. Cell stress response impairs de novo NAD+ biosynthesis in the kidney. JCI Insight. 2022;7(1):e153019. PubMed 34793337 · PMC8765040 · doi:10.1172/jci.insight.153019
- Raines NH, Cheung MD, Wilson LS, et al. Nicotinamide Adenine Dinucleotide Biosynthetic Impairment and Urinary Metabolomic Alterations Observed in Hospitalized Adults With COVID-19-Related Acute Kidney Injury. Kidney Int Rep. 2021;6(12):3002-3013. PubMed 34541422 · PMC8439094 · doi:10.1016/j.ekir.2021.09.001
- Mede AI, Milne GL, Wei D, et al. NAD+ Biosynthesis Impairment and Acute Kidney Injury after Major Vascular Surgery. Antioxidants (Basel). 2023;12(4):821. PubMed 37107195 · PMC10135380 · doi:10.3390/antiox12040821
- Piedrafita A, Balayssac S, Mayeur N, et al. The tryptophan pathway and nicotinamide supplementation in ischaemic acute kidney injury. Clin Kidney J. 2021;14(12):2490-2496. PubMed 34950461 · PMC8690092 · doi:10.1093/ckj/sfab050
- Guan Y, Wang SR, Huang XZ, et al. Nicotinamide Mononucleotide, an NAD+ Precursor, Rescues Age-Associated Susceptibility to AKI in a Sirtuin 1-Dependent Manner. J Am Soc Nephrol. 2017;28(8):2337-2352. PubMed 28246130 · PMC5533221 · doi:10.1681/ASN.2016040385
- Morevati M, Egstrand S, Nordholm A, et al. Effect of NAD+ boosting on kidney ischemia-reperfusion injury. PLoS One. 2021;16(6):e0252554. PubMed 34061900 · PMC8168908 · doi:10.1371/journal.pone.0252554
- Fontecha-Barriuso M, Lopez-Diaz AM, Carriazo S, et al. Nicotinamide and acute kidney injury. Clin Kidney J. 2021;14(12):2453-2462. PubMed 34950458 · PMC8690056 · doi:10.1093/ckj/sfab173
- Hasegawa K, Wakino S, Simic P, et al. Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes. Nat Med. 2013;19(11):1496-504. PubMed 24141423 · PMC4041199 · doi:10.1038/nm.3363
- Simic P, Vela Parada XF, Parikh SM, et al. Nicotinamide riboside with pterostilbene (NRPT) increases NAD+ in patients with acute kidney injury (AKI): a randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of NRPT in patients with AKI. BMC Nephrol. 2020;21(1):342. PubMed 32791973 · PMC7427083 · doi:10.1186/s12882-020-02006-1
- Raines NH, Ganatra S, Nissaisorakarn P, et al. Niacinamide May Be Associated with Improved Outcomes in COVID-19-Related Acute Kidney Injury: An Observational Study. Kidney360. 2021;2(1):33-41. PubMed 35368823 · PMC8785722 · doi:10.34067/KID.0006452020
- Ahmadi A, Begue G, Valencia AP, et al. Randomized crossover clinical trial of coenzyme Q10 and nicotinamide riboside in chronic kidney disease. JCI Insight. 2023;8(11):e167274. PubMed 37159264 · PMC10393227 · doi:10.1172/jci.insight.167274